Publication | Closed Access

Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I

Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderImmunologyPharmacologyHematologyHuman Multiple MyelomasMyeloid LeukemiasMyeloid NeoplasiaProteasome InhibitorAnti-cancer AgentOncologyRadiation OncologyCancer ResearchHealth Sciences